Navigation Links
Halozyme Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Stock
Date:2/15/2012

SAN DIEGO, Feb. 15, 2012 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced the completion of an underwritten public offering of 7,820,000 shares of its common stock, including 1,020,000 shares sold pursuant to the full exercise of an over-allotment option previously granted to the underwriter. All of the shares were offered by Halozyme at a price to the public of $10.61 per share. The proceeds to Halozyme from this offering were approximately $81.8 million, after deducting the underwriting discounts and commissions but before expenses. The Company anticipates using the net proceeds from the offering to build commercial inventory for anticipated product launches, fund research and development of proprietary programs, and for general corporate purposes. Barclays Capital Inc. acted as the sole book-running manager for the offering.

(Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

The shares described above were offered by Halozyme, pursuant to a shelf registration statement on Form S-3ASR filed with the Securities and Exchange Commission (the "SEC"), and automatically declared effective on February 9, 2012. A final prospectus supplement relating to the offering was also filed with the SEC.

Copies of the final prospectus supplement and accompanying prospectus may be obtained free of charge by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, you may obtain a final prospectus supplement from the offices of Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717; Barclaysprospectus@broadridge.com (phone: 888-603-5847).

This press release does not constitute an offer to sell, or the solicitation of a
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Halozyme Therapeutics Completes Enrollment in Chemophase Phase I/IIa Clinical Trial for Superficial Bladder Cancer
2. Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex
3. Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference
4. Halozyme Therapeutics Presents Findings on Combinations of rHuPH20 Enzyme With Bisphosphonates at the American Association for Cancer Research Conference
5. Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability
6. Halozyme Therapeutics Announces That Chemophase Meets Primary Endpoint in Phase I/IIa Clinical Trial
7. Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models
8. Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial and Selects Fourth Exclusive Biologic Target
9. Halozyme Therapeutics Begins Phase 1 Clinical Trial of Bisphosphonate Administered With rHuPH20 Enzyme
10. Halozyme Provides HYLENEX® Product Reintroduction Update
11. Halozyme Therapeutics Announces Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... SAN DIEGO , 29 septembre ... désignée Daiichi Sankyo) (TSE : 4568) et Ambit Biosciences ... d,un accord de fusion définitif en vertu duquel ... actions ordinaires en circulation d,Ambit Biosciences à 15 ... d,une offre publique d,achat qui sera suivie d,une ...
(Date:9/29/2014)...  Bob Pack, who lost his two young children ... Medical Association to immediately cease airing a television ad ... Mercury News called "shamelessly deceptive" and of which the ... believe about the measure is wrong." ... that doctors check California,s existing ...
(Date:9/29/2014)... Sept. 29, 2014  Volcano Corporation (Nasdaq: ... improving patient and economic outcomes on a global ... coronary and peripheral visualization, physiology diagnostics and therapies, ... Board of Directors from Engaged Capital, LLC.  The ... Volcano welcomes the perspectives of its ...
Breaking Medicine Technology:Daiichi Sankyo va acquérir Ambit Biosciences 2Daiichi Sankyo va acquérir Ambit Biosciences 3Daiichi Sankyo va acquérir Ambit Biosciences 4Daiichi Sankyo va acquérir Ambit Biosciences 5Daiichi Sankyo va acquérir Ambit Biosciences 6Daiichi Sankyo va acquérir Ambit Biosciences 7Daiichi Sankyo va acquérir Ambit Biosciences 8Daiichi Sankyo va acquérir Ambit Biosciences 9Father Calls On CA Medical Assn To Pull TV Ad Called "Jaw-Droppingly Deceptive" and "Baloney" By LA Times & "Shamelessly Deceptive" By San Jose Mercury News, Says Consumer Watchdog Campaign 2Father Calls On CA Medical Assn To Pull TV Ad Called "Jaw-Droppingly Deceptive" and "Baloney" By LA Times & "Shamelessly Deceptive" By San Jose Mercury News, Says Consumer Watchdog Campaign 3Father Calls On CA Medical Assn To Pull TV Ad Called "Jaw-Droppingly Deceptive" and "Baloney" By LA Times & "Shamelessly Deceptive" By San Jose Mercury News, Says Consumer Watchdog Campaign 4Father Calls On CA Medical Assn To Pull TV Ad Called "Jaw-Droppingly Deceptive" and "Baloney" By LA Times & "Shamelessly Deceptive" By San Jose Mercury News, Says Consumer Watchdog Campaign 5Volcano Issues Statement Regarding Letter From Engaged Capital 2Volcano Issues Statement Regarding Letter From Engaged Capital 3
... studied the treatment of pregnant women with hepatitis B virus ... study concluded that both the mothers benefited from treatment and ... weeks postbirth. The study presenter and co-investigator Calvin ... as hepatitis B is difficult to eradicate and currently there ...
... POINT, Calif., Nov. 1, 2010 The Global ... organization that aims to raise awareness about the ... 7,000 Bracelets for Hope™ campaign. The 7,000 Bracelets ... to an estimated 7,000 different chronic, life-threatening and ...
Cached Medicine Technology:Telbivudine Given to Mothers With Hepatitis B Reduces Infection Rate in Infants 2Telbivudine Given to Mothers With Hepatitis B Reduces Infection Rate in Infants 37,000 Bracelets For Hope™ - A Rare Disease Awareness Campaign 27,000 Bracelets For Hope™ - A Rare Disease Awareness Campaign 3
(Date:9/30/2014)... MN (PRWEB) September 30, 2014 ... leader in business technology and services was recognized ... First Call Effectiveness (FCE) in 2013. This prestigious ... properly the first time and for an extended ... For more than 20 years BEI Services has ...
(Date:9/30/2014)... Barbara Williamson shares her life story for the first ... Love, Sex and Commitment" . As co-founder with her ... successful and controversial Sandstone Retreat in Malibu, California, in ... what became known as the hub of the sexual ... popular, with a membership reaching 500 and nearly 8,000 ...
(Date:9/30/2014)... 2014 From October 12-15, MMS, ... the 2014 SHSMD Connections Annual Conference in San Diego, ... & Market Development (SHSMD) is proud to host the ... and communications, and strategic planning professionals in San Diego ... , The conference is a four-day event designed ...
(Date:9/30/2014)... Seattle, WA (PRWEB) September 30, 2014 ... Intelligence, proudly announced today that the Department of ... Office as its Enterprise End User Business ... to better support our nation’s veterans by enabling ... obtained through BI Office’s powerful enterprise analytics and ...
(Date:9/30/2014)... San Francisco, CA (PRWEB) September 30, 2014 ... places its main focus on ranking and reviewing all ... This website has officially announced the best liquid foundation ... Youth Liberator Serum Foundation is named as the best ... foundations cover drugstore as well as high end brands, ...
Breaking Medicine News(10 mins):Health News:Loffler Companies Rated Number One Among U.S. Dealers in Service “First Call Effectiveness” 2Health News:Loffler Companies Rated Number One Among U.S. Dealers in Service “First Call Effectiveness” 3Health News:The Autobiography "An Extraordinary Life: Love, Sex and Commitment" Embraces Healthy Sexual Behavior 2Health News:The Autobiography "An Extraordinary Life: Love, Sex and Commitment" Embraces Healthy Sexual Behavior 3Health News:MMS, Inc. (Medical Marketing Service) to Attend the 2014 SHSMD Connections Annual Conference in October 2Health News:U.S. Department of Veterans Affairs Takes Its Analytic Capabilities to the Next Level with BI Office from Pyramid Analytics 2Health News:Yves Saint Laurent is Named As Best Liquid Foundation 2014 2
... in heart attack or mortality rates , , SUNDAY, Nov. 4 ... to date, Harvard researchers report that they have found drug-eluting ... than bare metal stents do. , "There has been a ... investigator Dr. Laura Mauri, an assistant professor of medicine at ...
... ... Heart Association,s Scientific Sessions 2007 ... 4 , WHO: Dr. Amir Lerman, Professor of Medicine, Mayo Clinic, Rochester, MN ... Sweden Mr. Israel Schreiber, President ...
... North Carolina team of doctors, nurses, hospitals and emergency ... to provide faster, more effective treatment for heart attack ... fancy new equipment. But it does require competitors to ... move treatment forward empowering emergency services personnel in ...
... props open closed aortas in older patients, research suggests ... high-risk heart patients with narrowed aortas who typically need ... option -- an implanted, balloon-expandable aortic valve. , The ... the problem valve and then inflated, experts said. In ...
... increase in their risk of heart attacks or other ... the largest-ever study of the issue, being presented at ... Scientific Exposition in San Francisco. , Although donors are ... (hypertension) during follow-up, it is unclear whether this represents ...
... Union Election, Note Hospital System Failing ... to Live Up to its Own ... elected officials and other healthcare activists joined hospital,workers from the St. ... Hospital on Saturday, where they called for the health,system,s leadership to ...
Cached Medicine News:Health News:Drug-Coated Stents No Riskier in Long Run Than Bare Metal Ones 2Health News:Drug-Coated Stents No Riskier in Long Run Than Bare Metal Ones 3Health News:How Early Can We Detect Cardiovascular Disease Less Expensively ... Even in Childhood? 2Health News:RACE: a statewide model of better, faster heart attack care 2Health News:RACE: a statewide model of better, faster heart attack care 3Health News:Balloon Valve May Be Alternative to Open-Heart Surgery 2Health News:Balloon Valve May Be Alternative to Open-Heart Surgery 3Health News:No increase in cardiovascular risk for living kidney donors 2Health News:Healthcare Workers, Community Activists Call for Fair Election Agreement at St. Joseph Health System 2
... Aplicare's Saturated Swabsticks are packaged ... Each 4 inch Swabstick is saturated ... solution. Each package is terminally sterilized, ... the patient. It acts as a ...
... Antiseptic Antibacterial that does not ... 30 seconds, destroys over 99% ... for cleansing of minor wounds, ... disinfection of personal utensils and ...
... professional degerming, pre-op and post-op procedures. ... quaternary and substituted phenolic active ingredients ... and surfactants. Unprecedented efficacy on all ... 30 seconds. Techni-Care represents a new ...
Aplicare's disposable 1-ounce pouches are designed for individual application and are ideal for reducing waste. They are used in nursing homes, home healthcare settings, blood banks, laboratories, em...
Medicine Products: